MA42341A1 - Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale - Google Patents

Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale

Info

Publication number
MA42341A1
MA42341A1 MA42341A MA42341A MA42341A1 MA 42341 A1 MA42341 A1 MA 42341A1 MA 42341 A MA42341 A MA 42341A MA 42341 A MA42341 A MA 42341A MA 42341 A1 MA42341 A1 MA 42341A1
Authority
MA
Morocco
Prior art keywords
preparation
protein kinase
kinase inhibitor
medical use
mesomer
Prior art date
Application number
MA42341A
Other languages
English (en)
Other versions
MA42341B2 (fr
Inventor
Lei Yin
Wenjian Liu
Heng Li
Dianxi Zhu
Original Assignee
Gan&Lee Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58796287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42341(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan&Lee Pharmaceuticals filed Critical Gan&Lee Pharmaceuticals
Publication of MA42341A1 publication Critical patent/MA42341A1/fr
Publication of MA42341B2 publication Critical patent/MA42341B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne des composés tels que représentés dans la formule i ou un tautomère, un mésomère, un racémate, un énantiomère, un diastéréoisomère, un composé deutéré, un promédicament ou un mélange de ceux-ci, ou un sel ou un solvate pharmaceutiquement acceptable des composés tels que représentés dans la formule i ou un tautomère, un mésomère, un racémate, un énantiomère, un diastéréoisomère, un composé deutéré, un promédicament ou un mélange de ceux-ci, les r1 à r7 étant tels que définis
MA42341A 2015-11-30 2016-11-28 Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale MA42341B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510856641.1A CN106810536A (zh) 2015-11-30 2015-11-30 一种蛋白激酶抑制剂及其制备方法和医药用途
PCT/CN2016/107455 WO2017092635A1 (fr) 2015-11-30 2016-11-28 Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale

Publications (2)

Publication Number Publication Date
MA42341A1 true MA42341A1 (fr) 2018-06-29
MA42341B2 MA42341B2 (fr) 2021-05-31

Family

ID=58796287

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42341A MA42341B2 (fr) 2015-11-30 2016-11-28 Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale

Country Status (21)

Country Link
US (2) US11091476B2 (fr)
EP (1) EP3385262B1 (fr)
JP (2) JP6921101B2 (fr)
KR (1) KR20180083421A (fr)
CN (3) CN106810536A (fr)
AU (1) AU2016365366B2 (fr)
BR (1) BR112018010879A2 (fr)
CA (1) CA3002884A1 (fr)
CO (1) CO2018005854A2 (fr)
DK (1) DK3385262T3 (fr)
ES (1) ES2928169T3 (fr)
HU (1) HUE060152T2 (fr)
IL (1) IL259711B (fr)
MA (1) MA42341B2 (fr)
MX (1) MX387207B (fr)
PH (1) PH12018550049A1 (fr)
PT (1) PT3385262T (fr)
RU (1) RU2749437C2 (fr)
UA (1) UA124001C2 (fr)
WO (1) WO2017092635A1 (fr)
ZA (1) ZA201803531B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
US11440912B2 (en) 2017-10-27 2022-09-13 Fresenius Kabi Oncology Ltd Process for the preparation of ribociclib and its salts
CA3089592A1 (fr) 2018-02-15 2019-08-22 Nuvation Bio Inc. Composes heterocycliques utilises en tant qu'inhibiteurs de kinases
WO2019170055A1 (fr) * 2018-03-05 2019-09-12 上海海和药物研究开发有限公司 Composés ayant une activité inhibitrice de kinase cdk4/6, composition pharmaceutique de ceux-ci et utilisation de ceux-ci
BR112021015004A2 (pt) * 2019-01-29 2021-10-05 Beta Pharma, Inc. Derivados de 2 h-indazol como agentes terapêuticos para cânceres cerebrais e metastases cerebrais
CN114364668B (zh) * 2019-06-21 2024-07-16 甘李药业股份有限公司 Cdk4/6抑制剂、及其盐和中间体的制备方法
AR119184A1 (es) * 2019-06-21 2021-12-01 Gan & Lee Pharmaceuticals Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas
CN116113628A (zh) * 2020-08-31 2023-05-12 甘李药业股份有限公司 一种含cdk4/6抑制剂的药物组合物
CN116583283A (zh) * 2020-09-21 2023-08-11 普莱鲁德疗法有限公司 Cdk抑制剂及其作为药物的用途
JP2023554643A (ja) * 2020-12-18 2023-12-28 プレリュード・セラピューティクス・インコーポレイテッド Ｃｄｋ阻害剤及び医薬としてのその使用
CN112390793B (zh) * 2021-01-19 2021-04-27 中国药科大学 Cdk6/dyrk2双靶点抑制剂及其制备方法和应用
CN117222636A (zh) * 2021-04-12 2023-12-12 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物
CN117337284A (zh) * 2021-05-17 2024-01-02 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
WO2023040914A1 (fr) * 2021-09-14 2023-03-23 甘李药业股份有限公司 Utilisation pharmaceutique d'un inhibiteur de cdk4/6
WO2023116862A1 (fr) * 2021-12-24 2023-06-29 江苏恒瑞医药股份有限公司 Composé indole hydrogéné, son procédé de préparation et son utilisation médicale
CN115093397B (zh) * 2022-06-07 2023-09-05 自贡市第三人民医院 一种用于治疗肿瘤的化合物、合成方法及应用
CN117658987A (zh) * 2022-09-08 2024-03-08 上海深势唯思科技有限责任公司 作为plk1抑制剂的化合物及其制备方法和用途
CN119790049A (zh) * 2022-09-30 2025-04-08 楚浦创制（武汉）医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
US7091227B2 (en) 2000-02-07 2006-08-15 Abbott Gmbh & Co. Kg Benzothiazole derivatives
KR20060111716A (ko) * 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
JP2007520558A (ja) 2004-02-04 2007-07-26 スミスクライン・ビーチャム・コーポレイション キナーゼ阻害剤として有用なピリミジノン化合物
WO2007089768A2 (fr) 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines ou 4-aryl-2-aminoalkyl-pyrimidines utilisées comme modulateurs de la jak-2 et leurs procédés d'utilisation
WO2008124085A2 (fr) * 2007-04-03 2008-10-16 Exelixis, Inc. Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
WO2009017838A2 (fr) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinaisons d'inhibiteurs jak-2 et d'autres agents
LT2265607T (lt) * 2008-02-15 2017-03-27 Rigel Pharmaceuticals, Inc. Pirimidin-2-amino junginiai ir jų panaudojimas kaip jak kinazių slopiklių
EP2283009B1 (fr) * 2008-05-16 2012-08-29 F. Hoffmann-La Roche AG Inhibiteurs de la jnk
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2013173506A2 (fr) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Procédé de traitement d'une dégradation musculaire
US10112927B2 (en) * 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CA3072766A1 (fr) 2017-09-05 2019-03-14 Blackthorn Therapeutics, Inc. Derives de 2,6-diazaspiro[3.3]hepatane-2-yl et compositions pharmaceutiques connexes utiles comme antagonistes du recepteur de la vasopressine
CN117222636A (zh) 2021-04-12 2023-12-12 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物

Also Published As

Publication number Publication date
DK3385262T3 (da) 2022-10-10
WO2017092635A1 (fr) 2017-06-08
AU2016365366A1 (en) 2018-05-17
KR20180083421A (ko) 2018-07-20
EP3385262A4 (fr) 2019-06-19
CN108290864A (zh) 2018-07-17
RU2018122864A (ru) 2020-01-13
PT3385262T (pt) 2022-10-18
IL259711B (en) 2022-08-01
CA3002884A1 (fr) 2017-06-08
EP3385262A1 (fr) 2018-10-10
ZA201803531B (en) 2021-10-27
CN106810536A (zh) 2017-06-09
CO2018005854A2 (es) 2018-06-20
US11091476B2 (en) 2021-08-17
PH12018550049A1 (en) 2018-10-29
US11787801B2 (en) 2023-10-17
IL259711A (en) 2018-07-31
UA124001C2 (uk) 2021-07-07
MX387207B (es) 2025-03-18
US20200165239A1 (en) 2020-05-28
JP2021138737A (ja) 2021-09-16
CN108290864B (zh) 2022-05-10
MA42341B2 (fr) 2021-05-31
CN113956238A (zh) 2022-01-21
RU2018122864A3 (fr) 2020-03-17
HUE060152T2 (hu) 2023-02-28
JP2019500413A (ja) 2019-01-10
AU2016365366B2 (en) 2021-03-04
ES2928169T3 (es) 2022-11-15
EP3385262B1 (fr) 2022-07-13
CN113956238B (zh) 2023-07-14
BR112018010879A2 (pt) 2018-11-21
RU2749437C2 (ru) 2021-06-10
MX2018006370A (es) 2018-09-24
US20210371418A1 (en) 2021-12-02
JP6921101B2 (ja) 2021-08-18

Similar Documents

Publication Publication Date Title
MA42341A1 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
CL2019003154A1 (es) Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079)
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
BR112018011475A2 (pt) compostos e métodos para modulação de quinase e indicação para a mesma
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
PH12016501440A1 (en) Novel heterocyclic compounds
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA41607A (fr) Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
MA40302B1 (fr) Dérivés de carbazole
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
PE20240930A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
FR3087439B1 (fr) Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone)
MA39983A (fr) Dérivés de carboxamide
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
NZ767900A (en) Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA50093B1 (fr) Composé pentacyclique
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
FR3064634B1 (fr) Derives acryliques de 1 :4, 3 :6 dianhydrohexitol
MA58104B1 (fr) Procédé et intermédiaire pour la préparation d'oxétane-2-ylméthanamine